Safety evaluation of subcutaneous and intravenous administration of infliximab: a real-world study based on the FAERS database
BackgroundInflammatory Bowel Disease (IBD) is characterized by recurrent flare-ups, significantly impairing patients’ long-term quality of life and increasing the risk of complications. As the first chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), infliximab blocks TNF-α-m...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2026-06-01
|
| Colección: | Frontiers in Medicine |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fmed.2026.1834815/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|